Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
Purity: ≥98%
Macimorelin acetate (formerly AEZS-130; EP-1572; JMV-1843; trade name: Macrilen), the acetate salt form of Macimorelin, is a novel and potent synthetic small molecule growth hormone secretagogue receptor agonist approved in 2018 for use in the diagnosis of adult growth hormone deficiency. As a ghrelin agonist, it is orally active and stimulates the secretion of growth hormone (GH). As of December 2017, it became FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers.
ln Vivo |
In the IHKA mouse model, macimorelin perlite (5 mg/kg twice daily for 2 weeks) decreases the number and length of predictions [2].
|
---|---|
Animal Protocol |
Animal/Disease Models: Intrahippocampal kainic acid (IHKA) mouse model [2]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection, twice a day for two weeks. Experimental Results: The number and duration of seizures were Dramatically diminished during treatment, but there was no anti-epileptogenic or disease-modifying effect. |
References |
[1]. Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093.
[2]. An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28(9):3100-3112. [3]. Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34: |
Molecular Formula |
C28H34N6O5
|
|
---|---|---|
Molecular Weight |
534.62
|
|
CAS # |
945212-59-9
|
|
Related CAS # |
Macimorelin;381231-18-1
|
|
SMILES |
CC(C)(N)C(N[ C@H](CC1=CNC2=C1C=CC=C2)C(N[C@@H](NC=O)CC3=CNC4=C3C=CC=C4)=O)=O. CC(O)=O
|
|
Chemical Name |
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8705 mL | 9.3524 mL | 18.7049 mL | |
5 mM | 0.3741 mL | 1.8705 mL | 3.7410 mL | |
10 mM | 0.1870 mL | 0.9352 mL | 1.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.